Long noncoding RNA HOXA-AS2 promotes gastric cancer proliferation by epigenetically silencing P21/PLK3/DDIT3 expression

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33587-33601

  Xie, Min ^a   Sun, Ming ^a   Zhu, Ya Nan ^a   Xia, Rui ^a   Liu, Yan Wen ^a   Ding, Jie ^b   Ma, Hong Wei ^a   He, Xue Zhi ^a   Zhang, Zhi Hong ^a   Liu, Zhi Jun ^a   Liu, Xiang Hua ^a   De, Wei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; HOXA AS2; P21 PLK3 DDIT3; PRC2; Proliferation

Indexed keywords

GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HOXA CLUSTER ANTISENSE RNA2; LONG UNTRANSLATED RNA; POLO LIKE KINASE 3; PROTEIN P21; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DDIT3 PROTEIN, HUMAN; PLK3 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER STAGING; CELL GROWTH; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME INHIBITION; EPIGENETICS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HOXAAS2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH CARCINOGENESIS; TUMOR VOLUME; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL DIFFERENTIATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

AGED; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; RNA, LONG NONCODING; STOMACH NEOPLASMS; TRANSCRIPTION FACTOR CHOP; UP-REGULATION;

EID: 84946061874     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5599     Document Type: Article

References (47)

1. Herszenyi L and Tulassay Z. Epidemiology of gastrointestinal and liver tumors. EUR REV MED PHARMACOL SCI. 2010; 14:249-258.
2. Wang XN and Liang H. Some problems in the surgical treatment of gastric cancer. CHIN J CANCER. 2010; 29:369-373.
3. Saka M, Morita S, Fukagawa T and Katai H. Present and future status of gastric cancer surgery. JPN J CLIN ONCOL. 2011; 41:307-313.
4. Esteller M. Non-coding RNAs in human disease. NAT REV GENET. 2011; 12:861-874.
5. Ponting CP, Oliver PL and Reik W. Evolution and functions of long noncoding RNAs. CELL. 2009; 136:629-641.
6. An integrated encyclopedia of DNA elements in the human genome. NATURE. 2012; 489:57-74.
7. Kung JT, Colognori D and Lee JT. Long noncoding RNAs: past, present, and future. GENETICS. 2013; 193:651-669.
8. Gutschner T and Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA BIOL. 2012; 9:703-719.
9. Hu Y, Wang J, Qian J, Kong X, Tang J, Wang Y, Chen H, Hong J, Zou W, Chen Y, Xu J and Fang JY. Long noncoding RNA GAPLINC regulates CD44-dependent cell invasiveness and associates with poor prognosis of gastric cancer. CANCER RES. 2014; 74:6890-6902.
10. Yang F, Xue X, Zheng L, Bi J, Zhou Y, Zhi K, Gu Y and Fang G. Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. FEBS J. 2014; 281:802-813.
11. Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L, Xu TP, Xia R, Yang JS, De W and Chen J. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. ONCOTARGET. 2014; 5:2276-2292.
12. Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD, Kong R, Xia R, Lu KH, Li JH, De W, Wang KM and Wang ZX. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. MOL CANCER. 2014; 13:92.
13. Zhao H, Zhang X, Frazao JB, Condino-Neto A and Newburger PE. HOX antisense lincRNA HOXA-AS2 is an apoptosis repressor in all trans retinoic acid treated NB4 promyelocytic leukemia cells. J CELL BIOCHEM. 2013; 114:2375-2383.
14. Liao WT, Wang X, Xu LH, Kong QL, Yu CP, Li MZ, Shi L, Zeng MS and Song LB. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. CANCER-AM CANCER SOC. 2009; 115:1507-1517.
15. Wu Y, Grabsch H, Ivanova T, Tan IB, Murray J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, Lee M, Lee J, Koo JH, Yeoh KG, van Grieken N and Ylstra B, et al. Comprehensive genomic meta-analysis identifies intratumoural stroma as a predictor of survival in patients with gastric cancer. GUT. 2013; 62:1100-1111.
16. Busuttil RA, George J, Tothill RW, Ioculano K, Kowalczyk A, Mitchell C, Lade S, Tan P, Haviv I and Boussioutas A. A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response. CLIN CANCER RES. 2014; 20:2761-2772.
17. Kamminga LM, Bystrykh LV, de Boer A, Houwer S, Douma J, Weersing E, Dontje B and de Haan G. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. BLOOD. 2006; 107:2170-2179.
18. Margueron R and Reinberg D. The Polycomb complex PRC2 and its mark in life. NATURE. 2011; 469:343-349.
19. Simon JA and Kingston RE. Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. MOL CELL. 2013; 49:808-824.
20. Yuan W, Wu T, Fu H, Dai C, Wu H, Liu N, Li X, Xu M, Zhang Z, Niu T, Han Z, Chai J, Zhou XJ, Gao S and Zhu B. Dense chromatin activates Polycomb repressive complex 2 to regulate H3 lysine 27 methylation. SCIENCE. 2012; 337:971-975.
21. Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC, Kumar S, Cameron D, Sethi S, Ali-Fehmi R, Morris R, Bouwman DL, Munkarah AR, Weaver DW, Gruber SA and Batchu RB. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53. CANCER LETT. 2013; 336:53-60.
22. Chen J, Li J, Han Q, Sun Z, Wang J, Wang S and Zhao RC. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia. Exp Biol Med (Maywood). 2012; 237:1110-1116.
23. Bai J, Chen J, Ma M, Cai M, Xu F, Wang G, Tao K and Shuai X. Inhibiting enhancer of zeste homolog 2 promotes cellular senescence in gastric cancer cells SGC-7901 by activation of p21 and p16. DNA CELL BIOL. 2014; 33:337-344.
24. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR and Carroll AR, et al. Regulation of tumor angiogenesis by EZH2. CANCER CELL. 2010; 18:185-197.
25. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB and van de Vijver MJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. NATURE. 2010; 464:1071-1076.
26. Gibb EA, Brown CJ and Lam WL. The functional role of long non-coding RNA in human carcinomas. MOL CANCER. 2011; 10:38.
27. Sun M, Jin FY, Xia R, Kong R, Li JH, Xu TP, Liu YW, Zhang EB, Liu XH and De W. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC CANCER. 2014; 14:319.
28. Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, Sui H, Tang Y, Wang Y, Liu N, Ren J, Hou F and Li Q. Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. Br J Cancer. 2014; 111:736-748.
29. Wang KC, Yang YW, Liu B, Sanyal A, Corces-Zimmerman R, Chen Y, Lajoie BR, Protacio A, Flynn RA, Gupta RA, Wysocka J, Lei M, Dekker J, Helms JA and Chang HY. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. NATURE. 2011; 472:120-124.
30. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M, Attardi LD, Regev A, Lander ES, Jacks T and Rinn JL. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. CELL. 2010; 142:409-419.
31. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M and Xiong Y. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. ONCOGENE. 2011; 30:1956-1962.
32. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, Gil J, Walsh MJ and Zhou MM. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. MOL CELL. 2010; 38:662-674.
33. Zhao J, Ohsumi TK, Kung JT, Ogawa Y, Grau DJ, Sarma K, Song JJ, Kingston RE, Borowsky M and Lee JT. Genome-wide identification of polycomb-associated RNAs by RIP-seq. MOL CELL. 2010; 40:939-953.
34. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea MD, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, Regev A, Lander ES and Rinn JL. Many human large intergenic noncoding RNAs associate with chromatinmodifying complexes and affect gene expression. Proc Natl Acad Sci U S A. 2009; 106:11667-11672.
35. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. SCIENCE. 2002; 298:1039-1043.
36. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P and Kumar-Sinha C, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. SCIENCE. 2008; 322:1695-1699.
37. Ning X, Shi Z, Liu X, Zhang A, Han L, Jiang K, Kang C and Zhang Q. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. CANCER LETT. 2015; 359:198-205.
38. Gartel AL and Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. CANCER RES. 2005; 65:3980-3985.
39. Sherr CJ and Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. GENES DEV. 1995; 9:1149-1163.
40. Sherr CJ and Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. GENES DEV. 1999; 13:1501-1512.
41. Abbas T and Dutta A. p21 in cancer: intricate networks and multiple activities. NAT REV CANCER. 2009; 9:400-414.
42. Conn CW, Hennigan RF, Dai W, Sanchez Y and Stambrook PJ. Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian polo-like kinase, Plk3. CANCER RES. 2000; 60:6826-6831.
43. Iida M, Sasaki T and Komatani H. Overexpression of Plk3 causes morphological change and cell growth suppression in Ras pathway-activated cells. J BIOCHEM. 2009; 146:501-507.
44. Yoon MJ, Kang YJ, Lee JA, Kim IY, Kim MA, Lee YS, Park JH, Lee BY, Kim IA, Kim HS, Kim SA, Yoon AR, Yun CO, Kim EY, Lee K and Choi KS. Stronger proteasomal inhibition and higher CHOP induction are responsible for more effective induction of paraptosis by dimethoxycurcumin than curcumin. CELL DEATH DIS. 2014; 5:e1112.
45. Zhang P, Gao K, Tang Y, Jin X, An J, Yu H, Wang H, Zhang Y, Wang D, Huang H, Yu L and Wang C. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants. HUM MUTAT. 2014; 35:1142-1151.
46. UpdegraffBL and O'Donnell KA. Stressing the importance of CHOP in liver cancer. PLOS GENET. 2013; 9:e1004045.
47. Petiwala SM, Berhe S, Li G, Puthenveetil AG, Rahman O, Nonn L and Johnson JJ. Rosemary (Rosmarinus officinalis) extract modulates CHOP/GADD153 to promote androgen receptor degradation and decreases xenograft tumor growth. PLOS ONE. 2014; 9:e89772.